banner
ABOUT US
Aptacure Therapeutics Limited is a biotechnology company based in Hong Kong Science Park, aiming to develop innovative aptamer drugs to meet unmet medical need. Funded by the HKSAR Government's Innovation and Technology Commission (UIM/298 and UIM/328), the core technologies and products of the Aptacure are originated from the two universities by the following research groups: i) Hong Kong Baptist University, "Aptamer-based Translational Medicine and Drug Discovery" research group co-led by Prof

PRODUCT DESCRIPTION

Apc001

The company's Apc001 project is a nucleic acid aptamer drug developed for clinically validated targets in cooperation with Professor Zhang Ge from the Luo Shouhui Institute of Bone and Joint Disease Translational Medicine, Hong Kong Baptist University. It is expected to overcome the shortcomings of existing antibody drugs, and in 2019, it has obtained the US FDA orphan drug certification (FDA, DRU-2019-6966).

Apc002

An aptamer targeting Dickkopf1 (DKK1).

The joint project of The Sixth People's Hospital of Shanghai Jiao Tong University School of Medicine and Hong Kong Baptist University on " Clinical precision diagnosis and treatment of hereditary bone diseases based on molecular understandings" won the Fi

The joint project "Clinical precision diagnosis and treatment of hereditary bone diseases based on molecular understandings", applied by the Sixth People's Hospital of Shanghai Jiao Tong University School of Medicine...

The joint project of The Sixth People's Hospital of Shanghai Jiao Tong University School of Medicine and Hong Kong Baptist University on "Molecular Mechanisms and Clinical Precision Diagnosis and Treatment of Hereditary Bone Diseases" won the first prize

Imperial College London and Hong Kong Baptist University Mutations in specific structural regions of sclerostin were found to be closely linked to abnormal cardiovascular disease symptoms